Pharmaxis Ltd

Phoenix Gold Limited

Pharmaxis Ltd. is a pharmaceutical research company, which engages in the development and commercialization of healthcare products for fibrotic and inflammatory diseases. The company is headquartered in Frenchs Forest, New South Wales. The company went IPO on 2003-11-10. The firm has a productive drug discovery engine, drug candidates in clinical trials and two respiratory products approved in global markets. Its lead drug candidate, PXS-5505, is an orally taken drug that inhibits the lysyl oxidase family of enzymes. Its PXS-5505 is used for the treatment of the blood cancer myelofibrosis, which affects one in 500,000 people. PXS-5505 is also being investigated as a potential treatment for other cancers, such as liver and pancreatic cancer. The company also has two respiratory products: Bronchitol and Aridol. Bronchitol is used for the treatment of cystic fibrosis. Its other drugs in development include PXS-5382 (LOXL2 inhibitor), PXS-6302 (topical pan LOX inhibitor), PXS-4728 (SSAO inhibitor), PXS-4699 (dual SSAO/MAOB inhibitor) and PXS-5370 (dual SSAO/MPO inhibitor).

Magnis Energy Technologies Ltd. is engaged in the business of exploring, developing and mining natural flake graphite and manufacturing lithium-ion battey. The company is headquartered in Sydney, New South Wales and currently employs 7 full-time employees. The company went IPO on 2005-10-25. The firm supports and accelerates the adoption of electric vehicles and renewable energy storage critical for the green energy transition. The firm's subsidiary, Imperium3 New York, Inc (iM3NY), operates a Gigawatt scale Lithium-ion battery manufacturing project in Endicott, New York. The company also has a joint venture and lithium-ion research and development (R&D) technology partner, Charge CCCV LLC (C4V). iM3NY has commercialized C4Vs patented cathode chemistry to produce green credentialed lithium-ion battery cells for use in both electric vehicles and battery energy storage systems. The firm also has a 100% interest in the Nachu Project, which is a large-scale natural flake graphite project in Tanzania.

Magnis Energy Technologies Ltd

Actinogen Medical Ltd. is a clinical stage Australian biotechnology company, which focuses on the development of novel treatments or cognitive impairment associated with neurological, psychiatric, and metabolic diseases due to raised cortisol. The company is headquartered in Sydney, New South Wales. The company went IPO on 2007-10-16. The firm is engaged in the development of a therapy for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol. The company is engaged in the development of its lead compound, Xanamem, as a therapy for Alzheimer’s Disease, Major Depressive Disorder, Fragile X Syndrome, and other neurological diseases where reducing cortisol inside brain cells could have a positive impact. Xanamem’s mechanism of action is to block the production of cortisol inside cells through the inhibition of the 11B-HSD1 enzyme in the brain. Xanamem is designed to get into the brain after it is absorbed in the intestines upon swallowing its capsule. The company has studied 11B-HSD1 inhibition by Xanamem in approximately 300 volunteers and patients. The firm conducts a series of Phase II studies in multiple diseases to further confirm and characterize Xanamem’s therapeutic potential.

Actinogen Medical Limited

AFT Pharmaceuticals Ltd. engages in the development, licensing, and distribution of medical and pharmaceutical products. The firm develops, markets and distributes a portfolio of pharmaceutical products across a range of therapeutic categories around the world. The firm's segments include New Zealand, Australia, Asia and Rest of World. The firm's product portfolio targets various therapeutic areas, such as pain, eyecare, vitamins, allergy, gastrointestinal, dermatology and hospital. Its products include Maxigesic, ParaOsteo, ZoRub OA/HP, Fenpaed, Combolieve Day/Night, Hylo, Novatears, CromoFresh, Opti-soothe Wipes/Mask, VitAPOS, Ferro-liquid, FerroTab, Ferro-F, Ferro-sachets, Lipo VitC, Lipo VitD, CalciTab, Loraclear, Histaclear, Fexaclear, Levoclear, Allersoothe, Lorapaed, Becloclear, Steroclear, Gastrosoothe/Forte, LaxTab, Micolette, Nausicalm, DiaRelieve, Crystaderm, Crystawash Hand Sanitizer, Crystasoothe, ZoRub anti-chafing, Decazol, MycoNail and others.

Aft Pharmaceuticals Limited

Althea Group Holdings Ltd. is an investment company. The company is headquartered in Melbourne, Victoria. The company went IPO on 2018-09-21. The firm services these sectors via two business units: Althea and Peak Processing Solutions. Althea is its pharmaceutical business that offers a range of cannabis-based medicines which are made available to patients via prescription. Althea offers a range of education, access, and management services to support eligible patients and healthcare professionals in navigating medicinal cannabis treatment pathways. Peak Processing Solutions is its recreational cannabis business, which produces legal cannabis products purchased by adult consumers in retail stores. Peak Processing Solutions provides formulation and mass-manufacturing of recreational cannabis products, including beverages, concentrates, topicals and others. The firm operates in regulated and legal cannabis markets across Europe, North America, Australia, and Africa.

Althea Group Holdings Limited

GGUS.AX was created on 2015-08-17 by BetaShares. The fund's investment portfolio concentrates primarily on large cap equity. The Fund provides investors with a simple way to obtain a cost-effective geared exposure to the returns of the U.S. sharemarket, hedged to Australian Dollars.

The BetaShares Geared U.S. Equity Fund (GGUS) provides investors with a simple way to obtain a cost-effective geared exposure to the returns of the U.S. share market, hedged to Australian dollars.

A2B Australia Ltd. engages in the provision of taxi charge account and related services to the taxi industry. The company is headquartered in Alexandria, New South Wales.  The firm provides taxi network services to taxi operators and drivers nationally in Australia. Its network services include taxi booking services, full taxi fit outs and repairs, vehicle financing and insurance, as well as driver training and education. The Company’s mobility Services are provided under brands, including 13cabs, Silver Service and Maxi Taxi. The company provides integrated booking, payment and safety technologies to taxi and private hire businesses under brands, including Cabcharge and Mobile Technologies International. Its Cabcharge provides payment terminals enabling drivers to process non-cash trip payments. Its Mobile Technologies International provides a vehicle monitoring platform. The firm also provides payment consulting, software, processing and terminals under brands, including EFT Solutions, Spotto, Giraffe and FlamingoPay.

A2B Australia Limited

ARN Media Ltd is a AU-based company operating in Media industry. The company is headquartered in Macquarie, New South Wales.  ARN Media Limited, formerly HT&E Limited, is an Australia-based broadcast and on-demand audio company. The firm owns approximately 58 radio stations across 33 markets plus 46 digital audio broadcasting (DAB+) stations nationwide. The firm's portfolio of brands includes KIIS Network, Pure Gold Network, CADA, Regional, iHeartRadio, and iHeartPodcast Network. KIIS Network includes KIIS stations, KIIS 1065, KIIS 101.1, and KIIS 97.3. Pure Gold Network delivers a combination of music, intelligent content and timeless entertainment to the Gen X audience. Its digital entertainment platform iHeartRadio app is an all-in-one radio, music streaming, podcast, and live events platform available to Australians in every state. Audiences can also access their favorite stations in Australia from ARN, Special Broadcasting Service (SBS) and stations from New Zealand and the United States. Its iHeartPodcast Network Australia is the preeminent podcast destination for creators, brands and audiences.

Arn Media Limited

A200.AX was created on 2018-05-07 by BetaShares. The fund's investment portfolio concentrates primarily on large cap equity. The ETF currently has 2975.21m in AUM and 200 holdings. A200.AX aims to track the performance of an index (before fees and expenses) comprising 200 of the largest companies by market capitalisation listed on the ASX.

BetaShares Australia 200 ETF

Vanguard Australian Shares Index ETF seeks to track the return of the S&P/ASX 300 Index before taking into account fees, expenses and tax.

VAS.AX was created on 2009-05-04 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard Australian Shares Index ETF seeks to track the return of the S&P/ASX 300 Index before taking into account fees, expenses and tax.

Vanguard Australian Shares Index ETF (ASX: VAS) seeks to track the performance of the ASX 300 index before account fees, expenses, and taxes. The index tracks the top 300 companies on the Australian Securities Exchange (ASX). These are mostly large and established Australian companies. It is a popular choice among passive individual investors who don't have the time or the expertise to actively invest in stocks.

Vanguard Australian Shares Index Etf

VGS.AX was created on 2014-11-18 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard MSCI International Shares Index ETF seeks to track the return of the MSCI World ex-Australia Index (with net dividends reinvested) in Australian dollars before taking into account fees, expenses and tax.

Vanguard MSCI Index International Shares Etf

VDHG.AX was created on 2017-11-20 by Vanguard. The fund's investment portfolio concentrates primarily on target outcome asset allocation. Vanguard Diversified High Growth Index ETF seeks to track the weighted average return of the various indices of the underlying funds in which it invests, in proportion to the Strategic Asset Allocation, before taking into account fees, expenses and tax.

Vanguard Diversified High Growth Index ETF seeks to track the weighted average return of the various indices of the underlying funds in which it invests, in proportion to the Strategic Asset Allocation, before taking into account fees, expenses and tax.

VTS.AX was created on 2009-05-12 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard U.S. Total Market Shares Index ETF seeks to track the performance of the CRSP US Total Market Index, providing investors with exposure to a broadly diversified collection of securities that, in the aggregate, approximates the full index in terms of key characteristics.

Vanguard Us Total Market Shares Index Etf

IVV.AX was created on 2000-05-15 by iShares. The fund's investment portfolio concentrates primarily on large cap equity. The Fund aims to provide investors with the performance of an index, before fees and expenses. The index is designed to measure the performance of large capitalisation US equities.

The iShares S&P 500 ETF seeks to track the investment results of an index composed of large-capitalisation U.S. equities.

	PXS	A200
Last EOD price	$0.055	$120.79
YTD return	-8.33 %	3.00 %
1 month return	-8.33 %	-0.92 %
12 month return	N/A	N/A
10 years return	-94.71 %	N/A
10Y distribution/dividend return	0.00 %	0.00 %

	PXS	A200
Most recent distribution/dividend payout	N/A	N/A
Most recent payout date	Invalid Date	Invalid Date
Distribution/dividend frequency	Annually	Annually
Most recent distribution/dividend franked percentage estimate	N/A	N/A
12 months distribution/dividend yield	N/A	N/A
Average distribution/dividend payout	N/A	N/A
Average distribution/dividend yield per year	N/A	N/A
Average distribution/dividend franked percentage estimate	N/A	N/A

Compare AU

Compare PXS vs. A200

Overview

Performance

Industry & Region

Top Holdings

Performance

Growth History *

Historical returns

Distribution/dividend comparisons between PXS and A200